The inhibition of the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), as key immune checkpoint inhibitors, have been associated with a 6.5-year survival rate of 48% in patients with metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.